secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLUS THERAPEUTICS, INC. (PSTV)
CIK:        0001095981
Form:       8-K
Filed at:   2023-04-20T23:59:59+00:00
Accession:  0000950170-23-013672
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Plus Therapeutics Q1 2023 net loss $4.8M, cash $12.7M; completes ReSPECT-LM Phase 1/Part A
--------------------------------------------------------------------------------

- Completed Part A of ReSPECT-LM Phase 1/2a dose escalation trial for rhenium obisbemeda in leptomeningeal metastases.
- Q1 cash $12.7M vs $18.1M at Dec 31, 2022; net loss $0.14/share vs $0.19 prior year.
- Operating expenses $5.2M, up from $3.9M YoY, driven by $750K milestone payment to NanoTx Corp and clinical enrollment.
- Grant revenue $506K from CPRIT; total grant awards of $20.6M from NIH and CPRIT.
- Expects to present ReSPECT-GBM and LM data in H2 2023; planning to initiate pediatric trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1095981/000095017023013672/0000950170-23-013672-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1095981/000095017023013672/pstv-20230420.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-013672

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer